Micropime T 250mg/31.25mg Injection
Marketer
Micro Labs Ltd
Salt Composition
Cefepime (250mg) + Tazobactum (31.25mg)
Overview Micropime T 250mg/31.25mg Injection
This dual-antibiotic injection, Micropime T 250 mg/31.25 mg, combats bacterial infections by inhibiting microbial proliferation. Administered only by a healthcare provider, it requires adherence to the prescribed schedule; complete the entire course, regardless of symptom improvement. Potential side effects include gastrointestinal upset (nausea, vomiting, diarrhea), skin reactions (rashes), and localized injection site inflammation (redness, swelling, pain), typically resolving spontaneously. Severe reactions warrant immediate medical attention (e.g., allergic reactions manifesting as rash, itching, swelling, or respiratory distress). Inform your physician of all current medications, especially if pregnant or breastfeeding, before commencing treatment. Alcohol consumption should be avoided due to potential increased drowsiness. While generally non-impairing, driving should be avoided if drowsiness or dizziness occurs.
Uses of Micropime T 250mg/31.25mg Injection
Infections caused by bacteria
Major Benefits of Micropime T 250mg/31.25mg Injection:
This medication will be administered by your healthcare provider. Self-medication is not permitted.
Common Side effects of Micropime T 250mg/31.25mg Injection:
- Diarrhea
- Increased white blood cell count (eosinophils)
- Injection site phlebitis
- Skin rash
- Increased liver enzymes
- Positive Coombs test
How to use Micropime T 250mg/31.25mg Injection:
This medication will be administered by your physician or registered nurse; self-medication is strictly prohibited.
How Micropime T 250mg/31.25mg Injection works:
Micropime T Injection (250 mg/31.25 mg) unites Cefepime, a crucial antibiotic, with Tazobactum, a beta-lactamase inhibitor. Cefepime's mechanism involves disrupting bacterial cell wall synthesis, a process vital for bacterial viability. Tazobactum counteracts bacterial enzymes that would otherwise neutralize Cefepime, thus broadening Cefepime's effectiveness and overcoming bacterial resistance.
SAFETY ADVICE
AlcoholCAUTION
Exercise caution when using Micropime T 250 mg/31.25 mg Injection concurrently with alcohol. Seek medical advice before combining them.
PregnancySAFE IF PRESCRIBED
Micropime T 250 mg/31.25 mg Injection is typically deemed safe for use during gestation. Preclinical trials in animals revealed minimal or absent harm to the fetus; nevertheless, clinical data from human subjects are scarce.
Breast feedingSAFE IF PRESCRIBED
Micropime T 250 mg/31.25 mg Injection poses minimal risk during lactation. Research in humans indicates negligible transfer of the medication into breast milk, thereby presenting no appreciable danger to the infant.
DrivingUNSAFE
Following administration of Micropime T 250 mg/31.25 mg Injection, temporary blurred vision may occur. Refrain from driving until visual acuity returns to normal.
KidneyCAUTION
Exercise caution when administering Micropime T 250 mg/31.25 mg Injection to individuals with impaired renal function. Dosage modification for Micropime T 250 mg/31.25 mg Injection might be necessary. Physician consultation is recommended.
LiverSAFE IF PRESCRIBED
The use of Micropime T 250 mg/31.25 mg Injection in individuals with hepatic impairment appears to pose minimal risk. Preliminary evidence indicates dose modification may be unnecessary for this patient population. However, physician consultation is recommended.
What if you forget to take Micropime T 250mg/31.25mg Injection :
Omit Micropime T 250 mg/31.25 mg Injection doses necessitate physician consultation.
Facts to Know About Micropime T 250mg/31.25mg Injection
| Label | Value |
|---|---|
| Developing Habits | No. |
| Type of Treatment | Antimicrobial Agents |
3,018 People bought this recently